Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Completed · Phase 3 · Has a placebo group

Conditions studied: Desmoid Tumor, Aggressive Fibromatosis

In brief

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

Key facts

Study ID
NCT03785964
Run by
SpringWorks Therapeutics, Inc.
People needed
142
Starts
2019-04-17
Expected to finish
2024-10-17
Last updated by the study team
2025-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.